Prospective cross-sectional study using Poisson renewal theory to study phase singularity formation and destruction rates in atrial fibrillation (RENEWAL-AF): Study design

Jing Quah B MedSc MBBS, FRACP1,2,4 | Dhani Dharmaprani B Biomed Eng PhD1 | Anandaroop Lahiri MBBS1,2 | Madeline Schopp B Biomed Eng1 | Lewis Mitchell BMath, BSc, PhD3 | Joseph B. Selvanayagam MBBS (Hons) FRACP DPhil1,2,4 | Rebecca Perry BSc, PhD1,2,4 | Fahd Chahadi MBBS FRACP2 | Matthew Tung MBBS FRACP5 | Waheed Ahmad MBBS FRACP6 | Nikola Stoyanov MBBS FRACP7 | Majo X. Joseph MBBS FRACP1,2 | Cameron Singleton MBBS FRACP1,2 | Andrew D. McGavigan MBChB MD FRCP FRACP1,2 | Anand N. Ganesan MBBS FRACP PhD1,2,4

Abstract

Background: Unstable functional reentrant circuits known as rotors have been consistently observed in atrial fibrillation and are mechanistically believed critical to the maintenance of the arrhythmia. Recently, using a Poisson renewal theory-based quantitative framework, we have demonstrated that rotor formation ($\lambda_f$) and destruction rates ($\lambda_d$) can be measured using in vivo electrophysiologic data. However, the association of $\lambda_f$ and $\lambda_d$ with clinical, electrical, and structural markers of atrial fibrillation phenotype is unknown.

Methods: RENEWAL-AF is a multicenter prospective cross-sectional study recruiting adult patients with paroxysmal or persistent atrial fibrillation undergoing clinically indicated catheter ablation. Patients will undergo intraprocedural electrophysiologic atrial fibrillation mapping, with $\lambda_f$ and $\lambda_d$ to be determined from 2-minute unipolar electrogram recordings acquired before ablation. The primary objective will be to determine the association of $\lambda_f$ and $\lambda_d$ as markers of fibrillatory dynamics with clinical, electrical, and structural markers of atrial fibrillation clinical phenotype, measured by preablation transthoracic echocardiogram and cardiac magnetic resonance imaging. An exploratory objective is the noninvasive assessment of $\lambda_f$ and $\lambda_d$ using surface ECG characteristics via a machine learning approach.

Results: Not applicable.

Conclusion: This pilot study will provide insight into the correlation between $\lambda_f/\lambda_d$ with clinical, electrophysiological, and structural markers of atrial fibrillation phenotype and provide a foundation for the development of noninvasive assessment of...
1 | INTRODUCTION

Atrial fibrillation is the most common sustained cardiac arrhythmia in humans, affecting around 0.5% or 33.5 million individuals worldwide. Atrial fibrillation is associated with an increased risk of stroke, heart failure, dementia, and death. A critical clinical characteristic of atrial fibrillation is that it can be a progressive disease. In its early stages, atrial fibrillation episodes are typically short lasting and self-terminate. Over time, atrial fibrillation episodes may progressively become more sustained, with the final evolution of the disease into long-standing persistent or permanent atrial fibrillation. The clinical evolution of the atrial fibrillation phenotype has profound consequences, including a higher risk of stroke and death.

At a mechanistic level, atrial fibrillation is characterized by disorganized, aperiodic electrical wave propagation in the atrium. A key feature of atrial fibrillation dynamics is the presence of unstable functional reentrant circuits known as rotors. A limitation of contemporary phenotypic classification of atrial fibrillation is that the subtypes are based on indirect subjective reports of clinical arrhythmia behavior and management interventions, rather than being based on quantifiable properties of atrial fibrillation physiology or underlying fibrillatory dynamics.

Recently, we have demonstrated that rotational event formation and destruction rates can be accurately determined through characterization of the distributions of interformation event times and rotor lifetimes. In human and experimental models of cardiac fibrillation, we have shown that these consistently show exponential distributions. The exponential distribution is significant because it is the statistical signature of a Poisson renewal process. In a Poisson renewal process, the timing of individual events is independent, but the long-term event rate is fixed (Figure 1).

In that study, we demonstrated the feasibility of measuring rotor formation and destruction rates by fitting the distributions of phase singularity interformation event times and phase singularity lifetimes. We demonstrated these consistently followed exponential distributions in human atrial fibrillation, sheep atrial fibrillation and rat atrial fibrillation, and in an extension systematic review published with our study, we demonstrated that this has been a consistent finding observable in the published data of leading investigators in the field of atrial fibrillation and ventricular fibrillation research. The key implication of the exponential distribution identified in our study is that the formation and destruction of rotors occurs at relatively temporally stable rates, and in that study we demonstrated the feasibility of measuring this in both clinical and preclinical data.

The rationale for the current study is that because repetitive rotor regeneration and destruction is fundamental to the perpetuation of atrial fibrillation, the rate constants for rotor formation ($\lambda_f$) and rotor destruction ($\lambda_d$) could potentially be objective physiological markers of the underlying atrial fibrillation clinical phenotype. The study hypothesis is that clinical, electrical, and structural characteristics known to be associated with atrial fibrillation clinical phenotype will be associated with alterations in $\lambda_f$ and $\lambda_d$ as markers of fibrillatory dynamics. In the longer term, this will lay the foundation for $\lambda_f$ and $\lambda_d$ to be used as objective clinical markers of fibrillatory dynamics.

An essential practical consideration in future application of $\lambda_f$ and $\lambda_d$ for use as a clinical marker of atrial fibrillation electrophysiology is the development of a noninvasive approach to evaluating these measures. At present, $\lambda_f$ and $\lambda_d$ are measured through invasive catheter-based measurement during an electrophysiology study. As an additional secondary objective, simultaneously acquired surface ECG data will be utilized with a machine learning approach to develop a noninvasive measurement of $\lambda_f$ and $\lambda_d$. This will facilitate the development of $\lambda_f$ and $\lambda_d$ as noninvasive measures of fibrillatory dynamics that could be used to monitor atrial fibrillation progression.

The study has the potential to lead to a significant improvement in our understanding of cardiac fibrillation. It will lay the foundation for shifting clinical determination of atrial fibrillation phenotype to the characterization of the physiological processes underpinning the atrial fibrillation mechanism. Furthermore, it will determine the link between the current clinical understanding of atrial fibrillation phenotype and progression to underlying fibrillatory dynamics. Finally, it will provide initial validation of noninvasive surface ECG measurement of $\lambda_f$ and $\lambda_d$.

2 | METHODS

2.1 | Study population

RENEWAL-AF will be a nonrandomized prospective cross-sectional study analyzing the rates of rotor formation and rotor destruction preceding catheter ablation in patients with paroxysmal or persistent atrial fibrillation. Paroxysmal atrial fibrillation is defined as atrial fibrillation that terminates spontaneously or with intervention within 7 days of onset while persistent atrial fibrillation is defined as continuous atrial fibrillation that is sustained beyond 7 days. Patients with atrial fibrillation who have been referred for catheter...
ablation of atrial fibrillation will be recruited from cardiology outpatient’s clinic by their treating physicians (Figure 2).

2.2 Patient eligibility

2.2.1 Inclusion criteria

1. Patients referred for clinically indicated atrial fibrillation ablation. Clinical indication for atrial fibrillation ablation will be consistent with international guidelines.

2.2.2 Exclusion criteria

1. Patients unwilling to provide consent.
2. Presence of LA thrombus.
3. Previous ablations for atrial fibrillation.
4. Contraindications to anticoagulation therapy.

2.2.1 Inclusion criteria

a. Symptomatic atrial fibrillation refractory or intolerant to at least one class 1 or class 3 antiarrhythmic medication
b. Selected symptomatic patients with heart failure with or without reduced ejection fraction (EF).
2.3 | Informed consent

Informed consent will be obtained by researchers enrolled in this study on a preset date after the clinic review, upon expression of interest. All questions raised about this study will be discussed in detail during a review in the research clinic. Patients will be assured that participation in this study is entirely voluntary, and nonparticipation in this study will not affect their planned procedures. Patients who meet all the inclusion and exclusion criteria will be enrolled after providing written informed consent. All consent forms will be kept separate from clinical information worksheet so that it will not be possible to identify the patients. Personal information of participants will be kept confidential throughout.

2.4 | Preablation clinical phenotyping

Once written, informed consent has been obtained, patients will undergo a preablation assessment to define the presence of adverse atrial substrate. This includes an initial clinical assessment to define the following clinical variables: (a) hypertension, (b) diabetes mellitus, (c) obesity, (d) obstructive sleep apnea (OSA), (e) alcohol consumption (duration and amount), and (f) atrial fibrillation pattern and clinical duration. Patients will then undergo cardiac structural assessment. This includes an echocardiogram to measure indexed left atrial volume and diameter, left atrial strain, presence and grading of diastolic dysfunction, presence of left ventricular (LV) hypertrophy, and cardiac magnetic resonance imaging to determine the degree of left atrial fibrosis and EF.\(^{10}\)

2.4.1 | Electrophysiology study and ablation

Electrophysiologic studies will be performed at least five half-lives free from antiarrhythmic drugs, or in the case of patients taking amiodarone, encouraged to stop for at least 6 weeks or as long as can be tolerated. Patients will be mapped in spontaneous or induced AF using an electroanatomic mapping with the following parameters to be determined: (a) bipolar and unipolar electrogram voltage; and (b) presence and number of reduced (<1.5 mV), low-voltage (<0.5 mV), and scar points (<0.005 mV); (c) presence of complex electrograms, defined as >3 deflections and lasting >50 milliseconds.\(^{11}\) Mapping will be performed using a HD-grid catheter before ablation. The St Jude Medical Velocity electroanatomic mapping system will be utilized. Electrograms and ECG are recorded at 1000 Hz, with unipolar electrogram filter band pass set at 0.5–500 Hz. In patients presenting to the laboratory in sinus rhythm, AF will be induced using rapid atrial pacing maneuvers. Ablation will include pulmonary vein isolation with documentation of entrance and exit block. Additional lesions sets of linear ablation with or without SVC isolation will be at the discretion of the primary operator. Ablation at sites of fractionated electrograms will be avoided as a strategy for AF ablation.

2.5 | Signal acquisition and processing

Mapping will be performed using HD-grid catheter (Abbott) which is paddle-shaped, has four splines, with each spline containing four electrodes equidistant from each other. Digital 12-lead surface ECG data are recorded simultaneously to HD-grid 3-3-3-mm catheter data at 1000 Hz during the electrophysiology study and stored in Velocity 3D electroanatomic mapping system (St Jude Medical). Unipolar and bipolar electrogram recordings will be obtained in spontaneous or induced atrial fibrillation, with HD-grid catheter held in a stable position for 1 minute in locations throughout left and right atrium including the pulmonary veins, left atrial appendage, atrial septum, mitral isthmus, posterior wall, anterior wall, right atrial appendage, and right posterior wall. Electroanatomical data including electrograms, 3D data, and surface ECG will then be exported and processed using MATLAB. Signals will be filtered as previously described.\(^{12}\) Phase singularity detection will be performed

---

**FIGURE 2** Flow chart of patient recruitment into RENEWAL-AF
with an extended topological charge-based approach. A lookup table indexing onset and offset times and electrode location for each new phase singularity detection will be created to determine phase singularity lifetime and phase singularity interaction event times. Using a lookup table, computation of the histograms for phase singularity lifetimes and interaction event times will be performed. For each epoch, observed phase singularity lifetime data will be fitted using maximum likelihood and/or nonlinear least-squares regression and the phase singularity formation rate, $\lambda_f$, and destruction rate, $\lambda_d$, as previously described.

### 2.5.1 | Cardiac magnetic resonance imaging protocol

Cardiac magnetic resonance imaging will be performed before ablation using a 1.5T magnet. In brief, the cardiac magnetic resonance imaging acquisition protocol will be as follows: Following initial localizer and scout images, a full 3D cine short-axis (SA) stack will be performed for the LV and both atria using steady-state free precession images. Contrast-enhanced three-dimensional (3D) magnetic resonance angiography images will be used to define LA and pulmonary vein anatomy. Late gadolinium-enhanced (LGE) cardiac magnetic resonance imaging scans will be acquired 20 minutes following 0.2 mmol/kg gadolinium injection (Gadovist; Bayer Healthcare Pharmaceuticals). We will utilize a 3D inversion recovery prepared fast spoiled gradient recalled respiratory sequence triggered and navigated, ECG gated, and fat suppressed (repetition time of 2.5-5.5 milliseconds, echo time of 1.52 milliseconds, flip angle at 10°, in-plane resolution of $1.3 \times 1.3$, slice thickness of $2.0 \text{ mm}$, and inversion time of $240-290$ milliseconds).

### 2.5.2 | Cardiac magnetic resonance imaging analysis protocol

**Left atrial late gadolinium enhancement quantification**

The image intensity ratio (IIR), a previously described LGE-cardiac magnetic resonance imaging technique that normalizes myocardial image intensities by the mean blood pool intensity, corresponding to a bipolar voltage $\leq 0.3 \text{ mV}$ will be used to identify fibrosis. For this study, we will choose a threshold of $0.3 \text{ mV}$ to be consistent with prior studies of the extent of left atrial LGE. The methodology for calculation of the IIR and its validation against regional bipolar voltage has been previously described. The mean IIR of the entire left atrial and extent of fibrosis (as a percentage of total left atrial myocardium) will be measured for all patients. Left atrial volume will be calculated based on the 3D reconstruction of the left atrial contours.

### 2.6 | Echocardiography protocol

Comprehensive transthoracic echocardiography will be performed before electrophysiology study and ablation by experienced sonographers using a Vivid E95 ultrasound system or equivalent equipped with an M5S 3.5 mHz for transthoracic imaging. All recordings and measurements will be made according to the American Society of Echocardiography guidelines. Patients will be scanned in the left lateral decubitus position with standard 2D images consisting of three cardiac cycles triggered to the QRS complex saved in cine-loop digital format for offline analysis. LV mitral inflow velocities will be obtained by pulsed-wave Doppler echocardiography. Septal and lateral mitral annular early myocardial relaxation velocities will be obtained using Doppler tissue imaging from the apical four-chamber view for estimates of LV filling pressure. The left atrium will be imaged from the apical 4ch, 2ch, and long-axis views with care to ensure the left atrium is within the imaging sector, and the frame rate is between 50 and 80 frames per second. 3D datasets will be acquired from the apical window capturing the entire left atrium within the dataset.

Speckle-tracking strain analysis will be performed on the left atrium from the apical four-chamber, two-chamber, and long-axis views using Q-analysis (EchoPac Version 202, GE Vingmed Ultrasound). A region of interest will be the endocardial border of the left atrium and the tracking adjusted to cover the entire left atrium throughout the cardiac cycle. Only global strain will be utilized as regional strain is not practical in the left atrium because of the pulmonary vein orifices. Studies will be deemed inadequate for analysis when any part of the tracking is unable to follow the left atrial wall adequately. Reservoir, conduit, and contractile function will be determined following the EACVI/ASE/Industry Task Force recommendations to standardize deformation imaging. Left atrial volumes and 3D speckle tracking strain will be analyzed using LAQ (EchoPac Version 202, GE Vingmed Ultrasound). LV volumes and global longitudinal strain will also be assessed.

### 2.7 | Follow up

Patients will be followed up at the discretion by their treating physician.

### 2.8 | Outcomes

#### 2.8.1 | Primary outcome

The primary endpoints will be the association of each of the clinical, electrical, and structural characteristics with $\lambda_f/\lambda_d$.

#### 2.8.2 | Exploratory outcome

An exploratory endpoint will be the association between surface ECG characteristics with $\lambda_f/\lambda_d$, which will be explored using a feature engineering set/regression algorithm. For example, neural network architectures such as long-/short-term memory (LSTM) has been
shown to reveal patterns from high-dimensional time series conclusively and have been applied in regression contexts for ECG data. We will explore the use of LSTMs for supervised prediction of \( \lambda_f/\lambda_d \) from surface ECG data. Furthermore, modern unsupervised clustering techniques such as dynamic time warping and nonnegative matrix factorization will be used to explore if there is a relationship between quantifiable ECG features and the contemporary classification of atrial fibrillation. This will allow a noninvasive assessment of \( \lambda_f/\lambda_d \) from available surface ECG data.

2.9 | Sample size

Power analysis for multivariate regression was performed using the method. An \( R^2 \) of the reduced model was 0.40, with the full model including four covariates including atrial fibrillation type, bipolar voltage, cardiac magnetic resonance imaging LGE IIR, and indexed left atrial volume. Using a reduced alpha of 0.01, with a power 1-beta of 0.80, requires \( n = 41 \) subjects to be recruited.

2.10 | Data management and statistical analysis

Baseline demographics of patients, transthoracic echo, and cardiac magnetic resonance imaging data along with data acquired from the electrophysiological study will be entered electronically by researchers enrolled in this study at Flinders Medical Centre or at participating sites where the data originated. Original study forms and reports for cardiac imaging above will be kept on file at the participating site. Patients and associated clinical information will be identified electronically in the Excel worksheet only by their date of birth. Computers used for the research project will be password protected, and hard copies will be stored in locked cabinets. If clinical data are to be used for ancillary studies, additional consent will be obtained from the patient. Data integrity will be enforced through consistency checks against data stored in database and range checks. Modifications to the data written to the database will be documented through either the date change system or an inquiry system.

Continuous variables will be presented as mean and standard deviation, and categorical variables will be presented as percentage. A t-test (if normally distributed) or nonparametric test (if not normally distributed) will be used for continuous variables when conducting baseline comparisons. A \( P \) value of less than .05 will be considered statistically significant. The primary endpoint will be determined using multivariate linear regression. Clinical, imaging, and electrophysiological characteristics will be entered into the model using a stepwise block entry method to predict \( \lambda_f/\lambda_d \). Multicollinearity will be determined using a variable inflation factor analysis. Mid-term data analysis will be conducted after half the recruitment is finished, and the principal investigator will decide whether any measures need to be taken with the available results. Flinders Medical Centre will be responsible for the data, and other researchers have access to the data only after application and permission.

3 | RESULTS

3.1 | Ethical Issues

This clinical trial has been registered on the Australian New Zealand Clinical Trials Registry (ACTRN 12619001172190p). The study protocol (version 2.0 in February 2020) has been approved by the research ethics committee of Flinders Medical Centre, Adelaide, South Australia. The research ethics committee will also be responsible for supervising all procedures of the study, including participant recruitment, conduction, and data storage. In case of any changes to the study protocol, we will submit a written application to the research ethics committee.

4 | DISCUSSION

Atrial fibrillation is characterized by aperiodic, turbulent electrical wave propagation in the atrium.\(^5\) For over a century, the presence of unstable reentrant circuits has been a defining characteristic of atrial fibrillation.\(^15\)-\(^20\) Recently, we described a new approach based on renewal theory to enable measurement of rotor formation and destruction rates.\(^6\)

Here, we aim to conduct a prospective nonrandomized observational cohort study to define the association of clinical, imaging, and electrophysiologic characteristics with \( \lambda_f \) and \( \lambda_d \). A limitation of existing clinically based classification of atrial fibrillation patterns is that it has a limited quantitative resolution, and is unable to be followed longitudinally with time.\(^21\),\(^22\) The rationale for this approach is that it will lay the foundation for utilization \( \lambda_f \) and \( \lambda_d \) as objective clinical markers of fibrillatory dynamics.

At present, the dominant clinical classification of atrial fibrillation phenotype is based on clinical symptom profiles into temporal patterns, paroxysmal, or persistent.\(^21\),\(^22\) A limitation of this approach is that it is subjective,\(^21\) often inaccurate,\(^23\) and does not accurately predict progression.\(^21\) Thus, there is a need for more objective methods to accurately phenotype atrial fibrillation that are related to the underlying properties of electrical wave propagation.

Recently, we have shown that an exponential distribution of rotor phase singularity lifetimes is a conserved feature of human and experimental atrial fibrillation and ventricular fibrillation, validated with multiple modalities including electrogram-based and optical mapping.\(^8\) The exponential distribution is significant because it is the statistical signature of a Poisson stochastic renewal process.\(^9\) The universality of this finding, in not only our data but observable in underlying phase singularity data from multiple other
In this study, we seek to establish the relationship between \( \lambda_f \) and \( \lambda_d \) and assess this relation based on a temporal pattern. Although this is clinically based on atrial fibrillation (paroxysmal vs persistent) progression, the physiological parameter of rotor renewal rates. At present, we seek to modulate rates of rotor destruction and formation; (b) therapeutically, this could provide a new approach to the treatment of atrial fibrillation based on modulation of these rate constants.

5 | CONCLUSION

Development and validation of Poisson renewal theory as a tool to measure the formation and destruction of phase singularity in patients with atrial fibrillation represents a fundamental paradigm shift in the field of cardiac fibrillation. This study will provide crucial information linking conventional clinical, electrical, and structural markers of atrial fibrillation phenotype with \( \frac{\lambda_f}{\lambda_d} \) as a new, easily measurable markers of fibrillatory dynamics. Subsequently, validation of \( \frac{\lambda_f}{\lambda_d} \) from surface ECGs will allow noninvasive assessment of \( \frac{\lambda_f}{\lambda_d} \) in patients with atrial fibrillation not undergoing ablation, expanding the profile and utility of \( \frac{\lambda_f}{\lambda_d} \) as an objective marker of progression in clinical practice.

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article

ORCID

Jing Quah https://orcid.org/0000-0002-2268-1076

REFERENCES

1. Chugh SS, Havmoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847.
2. Oudotayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
3. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325.
4. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37(20):1591–602.
5. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415(6868):219–226.
6. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, AguinaLA, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia. 2017;33(5):369–409.
7. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.
8. Dharmapranl D, Schopp M, Kuklik P, Chapman D, Lahiri A, Dykes L, et al. Renewal theory as a universal quantitative framework to...
characterize phase singularity regeneration in mammalian cardiac fibrillation. Circulation: Arrhythmia and Electrophysiology. 2019;12: e007569.

9. Gallager RG. Discrete stochastic processes. J Oper Res Soc. 1997;48:103.

10. Zghaib T, Keramati A, Chrispin J, Huang D, Balouch MA, Ciuffo L, et al. Multimodal examination of atrial fibrillation substrate: correlation of left atrial bipolar voltage using multi-electrode fast automated mapping, point-by-point mapping, and magnetic resonance image intensity ratio. JACC Clin Electrophysiol. 2018;4(1): 87–96.

11. Prabhu S, Voskoboinik A, McLellan AJA, Peck KY, Pathik B, Nalliah CJ, et al. Biatrial electrical and structural atrial changes in heart failure: electroanatomic mapping in persistent atrial fibrillation in humans. JACC Clin Electrophysiol. 2018;4(1): 87–96.

12. Child N, Clayton RH, Roney CR, Laughner JI, Shuros A, Neuzil P, et al. Unraveling the underlying arrhythmia mechanism in persistent atrial fibrillation: results from the STARLIGHT study. Circ Arrhythm Electrophysiol. 2018;11(6): e005897.

13. Kuklik P, Zeemering S, van Hunnik A, Maesen B, Pison L, Lau DH, et al. Identification of rotors during human atrial fibrillation using contact mapping and phase singularity detection: technical considerations. IEEE Trans Biomed Eng. 2017;64(2):310–318.

14. Khurram IM, Beinart R, Zipunnikov V, Dewire J, Yarmohammadi H, Sasaki T, et al. Magnetic resonance image intensity ratio, a normalized measure to enable interpatient comparability of left atrial fibrosis. Heart Rhythm. 2014;11(1):85–92.

15. Allessie MA, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230–246.

16. Garrey WE. The nature of fibrillary contraction of the heart—its relation to tissue mass and form. American Journal of Physiology-Legacy Content. 1914;33(3):397–414.

17. Konings KT, Kirchoff CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89(4):1665–1680.

18. Berenfeld O, Mandapati R, Dixit S, Skanes AC, Chen J, Mansour M, et al. Spatially distributed dominant excitation frequencies reveal hidden organization in atrial fibrillation in the Langendorff-perfused sheep heart. J Cardiovasc Electrophysiol. 2000;11(8):869–879.

19. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation. 1997;95(2):511–521.

20. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J. 1964;67:200–220.

21. Lubitz SA, Benjamin EJ, Ruskin JN, Fuster V, Ellinor PT. Challenges in the classification of atrial fibrillation. Nat Rev Cardiol. 2010;7(8):451–460.

22. Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc. 2013;2(5):e000126.

23. Charitos EI, Purser J, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. J Am Coll Cardiol. 2014;63(25 Pt A):2840–2848.

24. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation. 2000;101(2):194–199.

25. Kneller J, Kalifa J, Zou R, Zaitsev AV, Warren M, Berenfeld O, et al. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res. 2005;96(5):e35–e47.

26. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802–809.

27. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation. Circ Cardiovasc Imaging. 2010;3(3):231–239.

28. Vianna-Pinton R, Moreno CA, Baxter CM, Lee KS, Tsang TSM, Appleton CP. Two-dimensional speckle-tracking echocardiography of the left atrium: feasibility and regional contraction and relaxation differences in normal subjects. J Am Soc Echocardiogr. 2009;22(3):299–305.

How to cite this article: Quah J, Dharmaprani D, Lahiri A, et al. Prospective cross-sectional study using Poisson renewal theory to study phase singularity formation and destruction rates in atrial fibrillation (RENEWAL-AF): Study design. J Arrhythmia. 2020;36:660–667. https://doi.org/10.1002/joa3.12363